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Abstract  Bovine  leukemia  virus  (BLV)  is  an  important  cattle  pathogen  that  causes  major  eco-
nomic losses  worldwide,  especially  in  dairy  farms.  The  use  of  animal  models  provides  valuable
insight into  the  pathogenesis  of  viral  infections.  Experimental  infections  of  sheep  have  been
conducted using  blood  from  BLV-infected  cattle,  infectious  BLV  molecular  clones  or  tumor-
derived cells.  The  Fetal  Lamb  Kidney  cell  line,  persistently  infected  with  BLV  (FLK-BLV),  is  one
of the  most  commonly  used  long-term  culture  available  for  the  permanent  production  of  virus.
FLK-BLV  cells  or  the  viral  particles  obtained  from  the  cell-free  culture  supernatant  could  be
used as  a  source  of  provirus  or  virus  to  experimentally  infect  sheep.  In  this  report,  we  aimed
to determine  the  minimum  amount  of  FLK-BLV  cells  or  cell-free  supernatant  containing  BLV
needed to  produce  infection  in  sheep.  We  also  evaluated  the  amount  of  antibodies  obtained
from a  naturally-infected  cow  required  to  neutralize  this  infection.  We  observed  that  both  sheep
experimentally  inoculated  with  5000  FLK-BLV  cells  became  infected,  as  well  as  one  of  the  sheep
receiving  500  FLK-BLV  cells.  None  of  the  animals  inoculated  with  50  FLK-BLV  cells  showed  evi-
dence of  infection.  The  cell-free  FLK-BLV  supernatant  proved  to  be  infective  in  sheep  up  to
a 1:1000  dilution.  Specific  BLV  antibodies  showed  neutralizing  activity  as  none  of  the  sheep
became infected.  Conversely,  the  animals  receiving  a  BLV-negative  serum  showed  signs  of  BLV
infection. These  results  contribute  to  the  optimization  of  a  sheep  bioassay  which  could  be  useful
to further  characterize  BLV  infection.a  de  Microbioloǵıa.  Published  by  Elsevier  España,  S.L.U.  This  is  an
he  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-© 2019  Asociación  Argentin
open access  article  under  tPlease  cite  this  article  in  press  as:  Porta  NG,  et  al.  Experimental  infection  of  sheep  with  Bovine  leukemia  virus  (BLV):
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Infección  experimental  en  ovinos  con  el  virus  de  leucosis  bovina:  dosis  mínima  de
células  BLV-FLK  y  virus  libre  de  células,  y  actividad  neutralizante  de  anticuerpos
naturales
Resumen  El  virus  de  la  leucosis  bovina  (bovine  leukemia  virus  [BLV])  es  un  importante  agente
patógeno del  ganado  que  causa  importantes  pérdidas  económicas  en  todo  el  mundo,  especial-
mente en  los  rodeos  lecheros.  El  uso  de  modelos  animales  proporciona  información  valiosa  sobre
la patogénesis  de  las  infecciones  virales.  Se  realizaron  infecciones  experimentales  en  ovejas
usando sangre  de  bovinos  infectados  con  BLV,  clones  moleculares  de  BLV  infecciosos  o  células
derivadas de  tumores.  La  línea  celular  Fetal  Lamb  Kidney,  persistentemente  infectada  con  el
BLV (FLK-BLV),  es  uno  de  los  cultivos  a  largo  plazo  más  utilizados  para  la  producción  permanente
de virus.  Las  células  FLK-BLV  o  las  partículas  virales  obtenidas  del  sobrenadante  del  cultivo  libre
de células  podrían  usarse  como  fuente  de  provirus  o  de  virus  para  infectar  experimentalmente
ovejas.  En  este  trabajo,  nuestro  objetivo  fue  determinar  la  cantidad  mínima  de  células  FLK-BLV
o de  sobrenadante  libre  de  células  que  contiene  BLV  necesaria  para  producir  infección  en  ove-
jas. También  evaluamos  la  cantidad  de  anticuerpos  bovinos  anti-BLV  necesaria  para  neutralizar
la infección.  Observamos  que  las  dos  ovejas  inoculadas  experimentalmente  con  5000  células
FLK-BLV se  infectaron,  y  que  una  de  las  dos  ovejas  que  recibieron  500  células  FLK-BLV  se  infectó.
Ninguno de  los  animales  inoculados  con  50  células  FLK-BLV  mostró  evidencia  de  infección.  El
sobrenadante  FLK-BLV  libre  de  células  demostró  ser  infectivo  en  ovejas  hasta  la  dilución  1:1000.
Los anticuerpos  BLV  específicos  mostraron  actividad  neutralizante,  ya  que  ninguna  de  las  ovejas
se infectó.  Por  el  contrario,  los  animales  que  recibieron  un  suero  BLV  negativo  mostraron  signos
de infección  por  BLV.  Estos  resultados  contribuyen  a  la  optimización  de  un  bioensayo  en  ovejas
útil para  caracterizar  la  infección  por  BLV.
© 2019  Asociación  Argentina  de  Microbioloǵıa.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un





















































ovine  leukemia  virus  (BLV)  is  a  retrovirus  that  belongs
o  the  Deltaretrovirus  genus  and  the  causative  agent  of
nzootic  bovine  leukosis  (EBL)  in  cattle  and  water  buffaloes,
heir  natural  hosts2.  The  infection  is  distributed  worldwide
nd  the  individual  prevalence  levels  of  infection  vary  among
nd  within  countries.  In  the  European  Union,  measures  of
ontrol  and  eradication  were  successful  in  most  Western
uropean  countries1,22,25.  Something  similar  occurred  in  New
ealand  and  Australia,  which  are  BLV-free  since  2008  and
013  respectively12.  In  the  Americas,  there  are  different  lev-
ls  of  BLV  prevalence;  in  the  case  of  Argentina,  more  than
0%  of  cattle  and  over  80%  of  dairy  farms  are  infected32
ith  an  individual  endemicity  higher  than  80%  in  areas  of
ntense  production19.  BLV  infection  is  a  serious  concern  since
t  causes  major  economic  losses  in  the  dairy  productive  sys-
em  and  in  international  trade9,30,32.
The  virus  can  infect  different  cells  of  the  immune  system
ut  has  a  preferential  tropism  for  B  lymphocytes.  There-
ore,  it  is  a  blood  borne  pathogen  as  Human  T-lymphotropic
irus  1  and  2  (HTLV-I  and  HTLV-II)2,31,  pathogens  from  the
ame  viral  family  with  genetic  and  antigenic  similarities.
ctive  viral  expression  occurs  during  the  first  stages  of
he  infection,  after  which  the  virus  remains  in  a  silentPlease  cite  this  article  in  press  as:  Porta  NG,  et  al.  Experime
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tate  in  the  infected  host,  permanently  integrated  into  the
ell  genome  as  provirus  DNA2,13.  This  produces  a  persistent





BLV  has  an  intense  transmission  dynamics.  All  practices
arried  out  without  blood  transmission  control,  such  as  blood
xtraction,  vaccination,  castration,  dehorning,  injection  of
edications,  rectal  palpation,  tattooing,  etc., are  routes
f  potential  infection,  and  animals  with  higher  levels  of
rovirus  in  blood  are  those  that  represent  a  higher  risk  for
ransmission8,21.
Most  of  the  infected  animals  are  asymptomatic  carriers
ince  they  do  not  exhibit  clinical  changes  and  their  leuko-
yte  count  remains  normal.  Between  20  and  30%  of  infected
nimals  develop  persistent  lymphocytosis  (PL)5,6,  which  is
haracterized  by  a  permanent  and  stable  increase  in  the
umber  of  circulating  peripheral  CD4  +  IgM  +  B  cells.  These
nimals  do  not  show  clinical  symptoms,  but  an  elevated
hite  blood  cell  count  can  be  observed  at  the  hematologi-
al  level37.  Of  all  the  infected  animals,  only  1--5%  of  them
evelop  fatal  lymphoma.  The  animals  develop  tumors  of  the
ymphatic  system  by  proliferation  of  B-cells,  mostly  affect-
ng  adult  cattle  (1--8  years  old)7.
Cattle  and  water  buffaloes  are  the  natural  hosts  of  BLV,
ut  there  are  some  species  that  can  be  experimentally
nfected  with  different  clinical,  hematological  and  immuno-
ogical  manifestations.  The  use  of  animal  models  is  very
mportant  as  they  allow  to  study  the  different  stages  of
iral  infection  along  with  the  progression  of  the  disease,
s  well  as  the  characterization  of  samples  for  their  infec-ntal  infection  of  sheep  with  Bovine  leukemia  virus  (BLV):
ation  activity  of  natural  antibodies.  Rev  Argent  Microbiol.
ivity,  protective  potential,  among  others.  In  rabbits,  the
nfection  is  in  most  cases  evidenced  by  the  manifestation
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BLV  genome.  In  some  rabbits,  a  decreased  T-cell  responsive-
ness  to  phytolectin  stimulation  and  signs  of  clinical  disease,
such  as  conjunctivitis,  rhinitis,  severe  weight  loss  and  unex-
pected  death,  can  be  also  observed28,39.  In  rats  and  swine,
the  experimental  infection  only  provokes  the  presence  of
anti-BLV  antibodies  as  the  virus  does  not  produce  pathogenic
effects3,20.  In  chickens,  anti-BLV  antibodies  can  be  found  in
all  experimentally  inoculated  animals23,  but  only  a  small
proportion  of  them  develop  leukemia4.  Goats  develop  per-
sistent  anti-BLV  antibodies  and  are  very  resistant  to  tumor
development,  although  after  a  long  period  of  time  (8  years),
death  by  lymphoma  can  be  observed  in  some  cases20,26.
Among  the  previously  described  animal  models,  sheep
particularly  exhibit  interesting  biological  features  for  eval-
uating  BLV  pathogenesis  and  also  for  diagnostic  purposes.
In  fact,  conversely  to  other  animal  models,  most  of  the
sheep  infected  with  BLV  develop  tumors  typical  of  the
disease.  Moreover,  sheep  usually  display  lymphosarcoma
symptoms  faster  (2.5  years  after  BLV  infection)  than  the
natural  hosts20,26.  Moreover,  most  of  the  experimentally-
inoculated  sheep  develop  persistent  B-cell  lymphocytosis
after  1.5  years11.  BLV  experimental  infection  of  sheep  has
been  successfully  performed  using  blood  from  BLV-infected
cattle,  in  vitro  produced  BLV  infectious  molecular  clones
or  cells  derived  from  tumors  of  infected  cattle20,24,27,29.
Although  some  cell  cultures  derived  from  different  animal
species  are  permissive  to  BLV,  infections  are  difficult  to  per-
form  as  they  produce  limited  quantities  of  virus  and  large
amounts  of  cellular  debris14,33.  The  Fetal  Lamb  Kidney  cell
line  persistently  infected  with  BLV(FLK-BLV),  established  by
Van  der  Maaten  and  Miller33,  is  one  of  the  most  commonly
used  long-term  culture  available  for  the  permanent  produc-
tion  of  virus.  FLK-BLV  cells  or  the  viral  particles  obtained
from  the  cell-free  culture  supernatant  (cell-free  BLV)  could
be  used  as  a  source  of  virus  to  experimentally  infect  sheep
and  other  species39.  Previous  reports  have  focused  the  use
of  the  sheep  model  on  the  study  of  BLV  pathogenesis,  the
process  of  leukemogenesis,  potential  treatments  to  elimi-
nate  tumors,  molecular  genetics  and  epigenetic  modulation
of  viral  expression,  also  the  association  with  HTLV16,17.  In  this
context,  no  information  was  found  in  the  literature  regard-
ing  the  minimum  infectious  dose  required  to  establish  the
infection  in  sheep  using  cell-free  FLK  supernatant  or  FLK-BLV
viable  cells.
The  aim  of  the  present  study  was  to  determine  the  effect
of  known  amounts  of  FLK-BLV  cells  or  cell-free  supernatant
obtained  from  FLK-BLV  cultures  in  sheep,  and  to  evaluate
the  amount  of  serum  antibodies  derived  from  a  naturally-
infected  cow  required  to  neutralize  BLV  infection.
Materials and methods
FLK-BLV  cell  culture
The  FLK-BLV  cell  line  was  generously  provided  by  Dr.  Luc
Willems  from  the  University  of  Liège,  Belgium.  The  FLK-
BLV  cell  line  grows  as  a  monolayer  and  has  4--7  copies  ofPlease  cite  this  article  in  press  as:  Porta  NG,  et  al.  Experimen
Minimum  dose  of  BLV-FLK  cells  and  cell-free  BLV  and  neutraliza
2019.  https://doi.org/10.1016/j.ram.2019.01.004
integrated  proviral  DNA  and  constantly  secretes  viral  parti-
cles  into  the  supernatant  without  any  cytopathogenic  effect,
which  allows  to  obtain  large  quantities  of  virus  with  a  small







n  RPMI  1640  medium  (Corning,  NY,  USA)  supplemented  with
%  of  inactivated  fetal  bovine  serum  (FBS,  Internegocios,
uenos  Aires,  Argentina)  until  the  formation  of  a  conflu-
nt  monolayer.  The  medium  was  then  replaced  with  RPMI
edium  supplemented  with  1%  FBS  to  reduce  the  amount
f  debris,  and  cultured  for  48  h.  The  cell-free  supernatant
ontaining  infectious  BLV  (cell-free  BLV)  was  harvested,  clar-
fied  by  centrifugation  at  3.000  rpm  for  15  min  and  stored  at
65  ±  10 ◦C  until  use.  Cells  were  harvested  by  trypsiniza-
ion,  washed  3  times  with  PBS  and  resuspended  in  RPMI
edium.  Viable  cells  were  counted  by  the  trypan  blue  exclu-
ion  method.  BLV  virus  (FLK-BLV  supernatant)  and  infected
ells  (FLK-BLV  cells)  were  used  as  inoculums  for  infection  in
ambs.
xperimental  sheep
ll  experiments  with  animals  were  performed  according  to
he  guide  on  the  care  and  use  of  laboratory  animals  of
he  National  Institutes  of  Health10.  The  procedures  followed
or  handling  of  animals,  extraction  and  handling  of  samples
ere  those  of  the  guidelines  described  in  the  Manual  of  the
nstitutional  Committee  for  Care  and  Use  of  Experimental
nimals  of  the  National  Institute  of  Agricultural  Technology
CICUAE-INTA).  Twenty-eight  3--6  month-old  BLV-free  lambs
Pampinta  breed)  were  used.  Lambs  were  kept  together  in  a
atural  grazing  system  until  the  end  of  the  study,  when  they
ere  euthanized.
xperimental  inoculations  of  sheep
ssay  A:  BLV-FLK  cells  and  cell-free  BLV  reducing
mounts
o  determine  the  minimum  amount  of  BLV-FLK  cells  or  cell-
ree  BLV  required  to  infect  sheep,  16  lambs  were  divided
nto  8 groups  (n  =  2  per  group)  and  experimentally  inocu-
ated  with  different  doses  of  FLK-BLV  cells  and  cell-free  BLV
Table  1).  These  inocula  were  obtained  by  serial  dilutions  in
PMI  medium  (Corning).  All  inocula  were  analyzed  by  nested
CR  (nPCR)  and  retrotranscriptase-nested  PCR  (RT-nPCR)
hat  amplifies  a fragment  of  the  BLV  TAX  gene  (described  in
ucleic  acid  extraction  and  amplification  section)  to  detect
he  provirus  and  the  virus,  respectively38.
Animals  were  subcutaneously  inoculated  in  the  armpit
ith  5  ml  of  each  inoculum.  Whole  blood  samples  with  EDTA
nticoagulant  were  taken  by  venous  puncture  of  the  jugular
he  day  of  the  experimental  infection,  and  30  and  60  days
ost-infection  (dpi).  Plasma  and  buffy  coat  were  obtained  by
entrifugation  at  2500  rpm  for  15  min  and  stored  at  −20 ◦C
ntil  analyzed.  All  inocula  were  analyzed  by  nPCR  and  RT-
PCR.
ssay  B:  neutralization  assay  with  antibodies  against  BLV
n  order  to  evaluate  the  neutralization  of  BLV  infection  with
ntibodies  present  in  serum  of  naturally  infected  cattle,  6
ambs  were  divided  into  3  groups  (n  =  2  per  group)  and  inoc-
lated  with  cell-free  BLV  diluted  1:10,  previously  incubatedtal  infection  of  sheep  with  Bovine  leukemia  virus  (BLV):
tion  activity  of  natural  antibodies.  Rev  Argent  Microbiol.
ith  different  amounts  of  a  BLV-positive  serum  (Groups
--11,  Table  2).  The  BLV-positive  serum  had  a  titer  of  antibod-
es  of  1/128  determined  by  ELISA  as  described  in  ‘‘Detection
f  BLV  antibodies’’  section.  As  a  positive  control,  6  lambs
ARTICLE IN PRESS+ModelRAM-326; No. of Pages 8
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Table  1  Inocula  used  in  assay  A:  BLV-FLK  cells  and  cell-free  BLV  reducing  amounts  (minimum  infectious  dose  assay).
Group  Inoculum  (5  ml)  Concentration/Dilutiona Provirus  (nPCR)  Viral  transcripts  (RT-nPCR)
1  FLK-BLV  cells 5000  cells  +  +
2 FLK-BLV  cells  50  cells  −  +
3 FLK-BLV  cells  50  cells  −  +
4 Cell-free  BLV  1:10  +  +
5 Cell-free  BLV  1:100  −  +
6 Cell-free  BLV  1:1000  −  +
7 Cell-free  BLV  1:5000  −  −
8 Cell-free  BLV  1:10000  −  −
a Number of cells or dilution of virus in RPMI medium in 5 ml of inoculum.
Table  2  Inocula  used  in  assay  B:  neutralization  assay  with  antibodies  against  BLV.
Group  Inoculum  (5  ml)  Relationa Provirus  (nPCR)  Viral  transcripts  (RT-nPCR)
Source  of  virus Bovine  serum
9  Cell-free  BLV  1:10  Positive  serum  1:1  +  +
10 Cell-free  BLV  1:10  Positive  serum  1:2  +  +
11 Cell-free  BLV  1:10  Positive  serum  1:4  +  +
12 Cell-free  BLV  1:10  Negativeserum  1:1  +  +
13 Cell-free  BLV  1:10  Negativeserum  1:2  +  +



















































a Relation in volume cell-free BLV: bovine serum.
ere  divided  into  3  groups  (n  =  2  per  group)  and  inoculated
nder  the  same  conditions  but  with  cell-free  BLV  diluted
:10,  previously  incubated  with  BLV-negative  serum  (Groups
2--14,  Table  2).  Animals  were  subcutaneously  inoculated
n  the  armpit  with  5  ml  of  each  inoculum.  Whole  blood  sam-
les  with  EDTA  anticoagulant  were  taken  by  venous  puncture
f  the  jugular  the  day  of  the  experimental  infection,  and
0  and  60  days  post-infection  (dpi).  Plasma  and  buffy  coat
ere  obtained  as  explained  above  and  stored  at  −20 ◦C  until
nalyzed.  All  inocula  were  analyzed  by  nPCR  and  RT-nPCR.
etection  of  BLV  antibodies
or  the  detection  of  BLV  antibodies,  an  in-house  ELISA
est  against  BLV  was  performed  (ELISA  LKF)  according  to
rono  et  al.32 Briefly,  ELISA  plates  were  coated  with  com-
lete  BLV  antigens  concentrated  from  FLK-BLV  cells  by
entrifugation  on  a  discontinuous  sucrose  gradient.  The
lasma  samples  previously  diluted  1/40  were  dispensed
nto  wells  in  duplicates.  After  incubation  and  washing,
nti-bovine  IgG  peroxidase  conjugated  was  added  to  each
ell.  The  presence  of  a  secondary  antibody  was  revealed
ith  3,3′,5,5′-tetramethylbenzidine  and  H2O2.  Reaction  was
topped  using  H2SO4 and  the  absorbance  was  read  at  450  nm.
ormalized  results  were  obtained  as  a  sample-to-positivePlease  cite  this  article  in  press  as:  Porta  NG,  et  al.  Experime
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atio.  A  weak  positive  control  serum  was  used  to  calcu-
ate  the  ratio;  its  reactivity  was  set  to  100%  and  all  tested






ucleic  acid  extraction  and  amplification
otal  RNA  from  inocula  and  whole  blood  samples  was
xtracted  using  the  High  Pure  RNA  Purification  Kit  (Roche,
enzberg,  Germany),  according  to  the  manufacturer’s
nstructions.  Extracted  RNA  was  treated  with  DNAses  prior
o  reverse  transcription  to  eliminate  DNA  contamination.
everse  transcription  was  carried  out  with  0.02  g/l  of  ran-
om  hexamers  (PROMEGA,  Fitchburg,  WI,  USA)  and  2.4  U/l
f  M-MLV  (PROMEGA).  The  cycling  conditions  of  the  RT-PCR
ere:  1  cycle  at  42 ◦C  for  60  min  and  1  cycle  at  95 ◦C  for
 min.  Total  genomic  DNA  was  extracted  using  the  High  Pure
CR  Template  Preparation  Kit  (Roche)  according  to  the  man-
facturer’s  instructions.
Partial  amplification  of  the  tax  gene  by  nPCR
as  performed  according  to  Wu  et  al.38,  using  cDNA
nd  DNA  samples  as  template.  Primers  TAX7781F
5′-CAGACACCAGGGGAGCCATA-3′) and  8083R  (5′-
TGCTAGCAACCAATTCGGA-3′)  were  used  in  the  first
ound,  and  primers  TAX7802F  (5′-AGCCATACGTTATCTCTCCA-
′)  and  TAX8062R  (5′-CAGGTTAGCGTAGGGTCATG-3′)  in  the
econd  round.  Positive  and  negative  controls  were  included
n  each  run.  RNA  samples  without  reverse  transcription
ere  analyzed  to  exclude  the  presence  of  genomic  DNA  in
NA  samples.  The  expected  size  of  the  amplified  product,
79  bp,  was  confirmed  by  fluorescent  nucleic  acid  gel  stain-
ng  (GelRed,  Biotium,  CA,  USA).  The  estimated  detection
imit  of  the  reaction  is  about  one  infected  cell  in  10000ntal  infection  of  sheep  with  Bovine  leukemia  virus  (BLV):
ation  activity  of  natural  antibodies.  Rev  Argent  Microbiol.
on-infected  cells.
ARTICLE IN PRESS+ModelRAM-326; No. of Pages 8
Experimental  infection  of  sheep  with  Bovine  leukemia  virus  (BLV)  5
Table  3  Detection  of  antibodies  and  proviral  DNA  at  different  times  post-infection  in  lambs  used  in  assay  A  (BLV-FLK  cells  and
cell-free BLV  reducing  amounts).













1  5000  FLK-BLV  cells  −  −  −  −  −  +
− −  −  +  +  +
2 500  FLK-BLV  cells −  −  −  −  −  +
− −  −  −  −  −
3 50  FLK-BLV  cells  −  −  −  −  −  −
− −  −  −  −  −
4 Cell-free  BLV  1/10  −  −  +  +  +  +
− −  +  +  +  +
5 Cell-free  BLV  1/100  −  −  +  +  +  +
− −  +  +  +  +
6 Cell-free  BLV  1/1000  −  −  −  +  +  +
− −  −  +  +  +
7 Cell-free  BLV  1/5000  −  −  −  −  −  −
− −  −  −  −  −
8 Cell-free  BLV  1/10000  −  −  −  −  −  −





























(−) Negative, (+) positive.
Results
Proviral  DNA  and  viral  transcripts  in  the
inoculation  material
BLV  provirus  was  detected  by  nPCR  in  the  cell-derived  inocu-
lum  containing  5000  FLK-BLV  cells  (Group  1,  Table  1) and  in
the  cell-free  BLV  diluted  1:10  (Group  4,  Table  1).  Viral  BLV
RNA  was  detected  in  the  FLK-BLV  cell  preparations  and  in
the  dilutions  1:10  to  1:1000  of  cell-free  BLV  (Groups  1--6,
Table  1).  Proviral  DNA  and  viral  BLV  RNA  were  detected  in  all
inocula  of  the  neutralization  assay  (Groups  9--14,  Table  2).
Sheep  infectivity
The  presence  of  BLV-specific  antibodies  in  the  plasma  of  the
inoculated  animals,  along  with  the  detection  of  circulating
BLV  proviral  DNA,  were  considered  indicators  of  infection  in
lambs.
Both  lambs  inoculated  experimentally  with  5000  FLK-BLV
cells  showed  evidence  of  infection  (2/2),  with  detection  of
provirus  and  antibodies  at  T60  post-infection.  With  500  FLK-
BLV  cells,  only  one  of  two  sheep  (1/2)  became  infected,  and
none  of  the  sheep  showed  evidence  of  infection  (0/2)  with
50  FLK-BLV  cells  at  the  end  of  the  trial.  The  cell-free  BLV
was  infective  down  to  1:1000  dilution  (2/2)  (Table  3).
In  the  neutralization  assay  (Table  4),  BLV  positive  serum
showed  a  neutralization  activity  when  it  was  previously  incu-
bated  with  cell-free  BLV,  as  no  sheep  showed  evidence  ofPlease  cite  this  article  in  press  as:  Porta  NG,  et  al.  Experimen
Minimum  dose  of  BLV-FLK  cells  and  cell-free  BLV  and  neutraliza
2019.  https://doi.org/10.1016/j.ram.2019.01.004
infection.  As  positive  controls,  the  lambs  inoculated  with
cell-free  BLV  when  previously  incubated  with  negative  serum
in  relation  showed  evidence  of  infection  1:1  (2/2),  1:2  (2/2)






LK-BLV  cells  are  a  persistently  infected  cell  line,  with
he  integrated  proviral  BLV  genome,  which  secretes  viral
articles  into  the  supernatant  with  minimum  cell  debris.
revious  studies  have  shown  that  this  cell  line  is  a  good
hoice  for  experimental  infection  assays.  However,  the  ear-
ier  reported  articles  showed  poor  details  about  the  amounts
nd/or  dilutions  used  for  inoculation,  regarding  starting
aterials,  viable  cells  or  cell-free  supernatants19,26. Thus,  in
he  present  study,  cell-free  BLV  and  FLK-BLV  cells  were  used
s  source  of  virus  and  provirus,  respectively,  in  different
mounts.
Previous  results  from  our  laboratory  have  shown  that  the
ell  culture  supernatant  contains  the  maximum  concentra-
ion  of  BLV  particles  48  h  after  the  monolayer  has  reached
00%  confluence.  Afterwards,  the  concentration  decreases
s  the  particles  begin  to  degrade.  A  semiquantification  using
erial  dilutions  of  different  FLK-BLV  cell  supernatants  up  to
he  dilution  1:1000  sowed  to  be  positive  by  RT-PCR  (data
ot  shown).  Consequently,  although  the  exact  number  of
iral  particles  used  in  the  inocula  could  not  be  estimated
ince  in  vitro  viral  titration  assays  are  not  available,  the  pro-
ocol  for  collecting  FLK-BLV  supernatant  used  in  this  study
as  been  previously  optimized  by  our  group  to  obtain  the
aximum  amount  of  viral  particles.
The  presence  of  BLV-specific  antibodies  in  the  plasma  of
noculated  lambs,  along  with  the  detection  of  BLV  provi-
al  DNA,  indicates  that  our  experimental  approaches  based
n  FLK-BLV  cells  or  cell-free  BLV  were  successful  in  estab-
ishing  the  infection  with  the  virus  in  lambs.  As  expected,tal  infection  of  sheep  with  Bovine  leukemia  virus  (BLV):
tion  activity  of  natural  antibodies.  Rev  Argent  Microbiol.
he  dose  response  effect  observed  showed  a  reduction  in
nfectivity  for  both  initial  materials  at  higher  dilutions.  The
resence  of  proviral  DNA  in  the  absence  of  antibodies  in
he  500  FLK  cell  inoculum  suggests  that  as  template.  In  this
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Table  4  Detection  of  antibodies  and  proviral  DNA  at  different  times  post-infection  in  lambs  used  in  assay  B  (neutralization
assay with  antibodies  against  BLV).













9 Cell-free  BLV  1:10  +  BLV  positive
Serum  (+)  1:1
−  −  −  −  −  −
− −  −  −  −  −
10 Cell-free  BLV  1:10  +  BLV  positive
Serum  (+)  1:2
−  −  −  −  −  −
− −  −  −  −  −
11 Cell-free  BLV  1:10  +  BLV  positive
Serum  (+)  1:4
−  −  −  −  −  −
− −  −  −  −  −
12 Cell-free  BLV  1:10  +  Serum  (−)  1:1 −  −  +  +  +  +
− −  +  +  +  +
13 Cell-free  BLV  1:10  +  Serum  (−)  1:2 −  −  +  +  +  +
− −  −  +  +  +
14 Cell-free  BLV  1:10  +  Serum  (−)  1:4 −  −  −  +  +  +






































































(−) Negative, (+) positive.
ense,  a  syncytium  assay  was  used  in  the  past  for  the  detec-
ion  of  neutralizing  antibodies  using  the  CC81  cell  line  as
ndicator  culture  and  the  FLK  cell  line  as  effector  culture,
oth  in  the  presence  of  bovine  or  sheep  serum  that  provokes
yncytium  inhibition  in  the  CC81  culture  in  the  case  of  neu-
ralization  activity15.  This  approach  was  not  reproducible
n  our  hands;  nevertheless,  we  took  great  care  in  assaying
ultiple  variables  (data  not  shown).
Without  an  in  vitro  viral  titration  system  and  an  in  vitro
ssay  for  the  detection  of  the  neutralizing  activity,  and  with
he  need  to  find  a  way  to  proceed  in  future  experiments,
e  decided  to  advance  with  the  previously  reported  in  vivo
ssays  using  sheep.  Even  if  the  bovine  is  the  natural  host  of
LV  infection,  this  species  is  not  the  choice  for  characteri-
ation  assays  such  as  viral  titration  or  neutralizing  antibody
etection.  Neither  is  the  choice  for  reproducing  the  disease,
s  the  progression  of  infection  is  slow  and  only  a  small  per-
entage  of  the  infected  animals  develop  fatal  lymphoma
fter  long  subclinical  periods.  Experimental  transmissions
ave  been  reported  in  many  species  with  different  clin-
cal,  hematological  and  immunological  manifestations.  In
his  respect,  the  sheep  model  has  proven  to  be  very  useful
n  terms  of  obtaining  information  regarding  immunity,  viral
ersistence  and  pathogenesis.  The  asymptomatic  period  in
heep  is  much  shorter  than  in  cattle,  with  100%  of  the
xperimentally-infected  sheep  developing  persistent  lym-
hocytosis  and  most  of  them  progressing  to  the  development
f  lymphosarcomas  around  18  months  post-infection.  This
odel  has  been  widely  used  not  only  for  the  analysis  of  nat-
ral  samples  but  also  to  test  the  infectivity  and  pathogenesis
f  BLV  molecular  clones34--36.  Furthermore,  considering  the
lose  proximity  of  BLV  with  HTLV  I  and  HTLV  II,  the  sheep
odel  was  used  for  experimental  treatments16,17.
The  results  presented  in  this  work  contribute  to  the  opti-
ization  of  a  sheep  bioassay  used  to  further  characterizePlease  cite  this  article  in  press  as:  Porta  NG,  et  al.  Experime
Minimum  dose  of  BLV-FLK  cells  and  cell-free  BLV  and  neutraliz
2019.  https://doi.org/10.1016/j.ram.2019.01.004
he  BLV  infection.  Particularly,  the  aim  of  this  work  was  to
etermine  the  minimum  number  of  FLK-BLV  cells  or  cell-free
LV  necessary  to  induce  infection  in  sheep  and  to  determine





eutralize  the  experimental  infection.  This  approach  can  be
seful  as  it  can  be  used  in  a  wide  range  of  experiments  such
s  testing  infectivity  and/or  the  protective  potential  of  dif-
erent  samples,  as  well  as  for  the  study  of  viral  pathogenesis.
n  fact,  we  are  currently  using  this  approach  for  the  analysis
f  the  BLV-inactivating  potential  of  heat  treatments  of  milk
nd  colostrum18.
The  minimum  infectious  dose  is  the  minimum  estimated
umber  of  organisms  required  to  produce  infection  in  ani-
als  exposed  by  a  given  route.  In  the  assay  done  in  this
ork,  we  were  able  to  determine  the  minimum  infectious
ose  of  provirus  and  virus  using  both  FLK-BLV  cells  and  cell-
ree  BLV.  In  both  cases,  as  the  inocula  were  more  diluted,
he  time  of  appearance  of  evidence  of  infection  was  longer,
nd  the  first  indication  of  this  was  the  detection  of  provi-
al  BLV  genome  by  nPCR  and  later  the  detection  of  specific
ntibodies  against  BLV  by  ELISA.
The  results  of  the  neutralization  assay  indicate  that  the
erum  of  a  BLV-free  animal  did  not  interfere  with  the  infec-
ion  process.  The  exception  was  the  last  inoculum  with  the
ighest  amount  of  serum  that  suggests  unspecific  serum
oxicity.  We  conclude  that  the  assay  should  not  be  per-
ormed  at  1:4  or  higher  proportions,  as  in  the  case  of  a
LV-infected  animal,  it  would  not  be  possible  to  state  if  the
esult  is  a  consequence  of  the  presence  of  specific  antibod-
es  or  of  the  unspecific  effect  of  the  serum  itself.  When
LV-positive  serum  (titer  1/128)  was  added,  all  the  pro-
ortions  were  capable  of  protecting  the  lambs  against  the
irus.
This  work  allowed  us  to  progress  toward  the  setup  of  fea-
ible  assays  to  detect  infectivity  and  neutralizing  antibodies
n  addition  to  the  previously  reported  syncytium  assay  which
as  shown  to  be  not  easy  to  perform,  insidious  to  read  and
ven  difficult  to  reproduce.  The  sheep  bioassay  is  important
or  future  experiments  and  projects  in  our  research  groupntal  infection  of  sheep  with  Bovine  leukemia  virus  (BLV):
ation  activity  of  natural  antibodies.  Rev  Argent  Microbiol.
hat  needs  to  characterize  and  state  parameters  derived
rom  natural  and/or  experimental  infections.  Prior  to  this
ork,  we  performed  the  experimental  inoculations  using
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containing  a  confluent  monolayer  of  FLK-BLV  cells  (cells  and
supernatant);  now,  we  know  the  limit  of  infection  of  both
cell-free  BLV  and  viable  FLK-BLV  cells.  Together  with  the
positive  detection  of  neutralizing  activity,  we  are  ready  to
progress  toward  experiments  that  can  make  use  of  this  help-
ful  tool.
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